Insider · CIK 0002127908
David Parrot
Files at SCTX (Scribe Therapeutics, Inc.). First filing Jul 27, 2026, latest Jul 27, 2026.
In brief
David Parrot files SEC Form 4 as CFO at SCTX (Scribe Therapeutics, Inc.). Since Jul 27, 2026, David Parrot has reported 1 open-market buy worth $40k and 0 open-market sells worth $0, the latest filed on Jul 27, 2026.
A track record needs three past buys with six months of prices behind them; David Parrot has 0, so none is measured yet.
The newest scored trade: bought $40k of SCTX on Jul 23, 2026, filed Jul 27, 2026, scored 51 (moderate). In the last 12 months: 1 buy worth $40k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SCTX: Scribe Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Scribe Therapeutics, Inc. | $40k 2,666 shares | - | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By Spouse | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By Child | +1,333 | $15.00 | $20k | 1,333 | Jul 27, 2026 |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,909 | $0.00 | $0 | 8,909 | Jul 27, 2026 |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | AGrant or award Performance-based Stock Option (Right to Buy)derivative | +109,426 | $0.00 | $0 | 109,426 | Jul 27, 2026 |
Questions about David Parrot
Answered from the filings on this page, as of the latest one.
Is David Parrot buying or selling?
In the last 12 months David Parrot reported 1 open-market buy worth $40k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $40k of SCTX on Jul 23, 2026. Grants, option exercises and tax withholding are not counted.
How did David Parrot's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Parrot has 0.
Where does David Parrot file Form 4?
David Parrot has filed Form 4 at SCTX (Scribe Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.